Applications of emerging molecular technologies in glioblastoma multiforme

References

• Frosch MP, Anthony DC, Girolami UD. The Central Nervous System. In: Robbins and Cotran Pathologic Basis of Disease (7th Edition). Kumar V, Abbas AK, Fausto N (Eds). Elsevier Saunders, PA, USA 1401–1410 (2005).
   Google Scholar
• Rosell R, de Las Peñas R, Balaña C et al. Translational research in glioblastoma multiforme: molecular criteria for patient selection. Future Oncol.4(2), 219–228 (2008).
   PubMed Web of Science ®Google Scholar
• Lacroix M, Abi-Said D, Fourney DR et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J. Neurosurg.95(2), 190–198 (2001).
   PubMed Web of Science ®Google Scholar
• Buckner JC. Factors influencing survival in high-grade gliomas. Semin. Oncol.30(Suppl. 19), 10–14 (2003).
   PubMed Web of Science ®Google Scholar
• DeAngelis LM. Brain tumors. N. Engl. J. Med.344(2), 114–123 (2001).
   PubMed Web of Science ®Google Scholar
• Walker MD, Alexander E Jr, Hunt WE et al. Evalutation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial. J. Neurosurg.49(3), 333–343 (1978).
   PubMed Web of Science ®Google Scholar
• Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science270(5235), 467–470 (1995).
   PubMed Web of Science ®Google Scholar
• Houillier C, Lejeune J, Benouaich-Amiel A et al. Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer106(10), 2218–2223 (2006).
   PubMed Web of Science ®Google Scholar
• Karlbom AE, James CD, Boethius J et al. Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10. Hum. Genet.92(2), 169–174 (1993).
   PubMed Web of Science ®Google Scholar
• Rasheed BK, McLendon RE, Friedman HS et al. Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. Oncogene10(11), 2243–2246 (1995).
   PubMed Web of Science ®Google Scholar
• Fults D, Pedone CA, Thompson GE et al. Microsatellite deletion mapping on chromosome 10q and mutation analysis of MMAC1, FAS, and MXI1 in human glioblastoma multiforme. Int. J. Oncol.12(4), 905–910 (1998).
   PubMed Web of Science ®Google Scholar
• Homma T, Fukushima T, Vaccarella S et al. Correlation among pathology, genotype, and patient outcomes in glioblastoma. J. Neuropathol. Exp. Neurol.65(9), 846–854 (2006).
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, van den Bent MJ et al. Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist11(2), 165–180 (2006).
   PubMed Web of Science ®Google Scholar
• Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc. Natl Acad. Sci. USA84(19), 6899–6903 (1987).
   PubMed Web of Science ®Google Scholar
• Ekstrand AJ, Sugawa N, James CD, Collins VP. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl Acad. Sci. USA89(10), 4309–4313 (1992).
   PubMed Web of Science ®Google Scholar
• Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am. J. Pathol.170(5), 1445–1453 (2007).
   PubMed Web of Science ®Google Scholar
• Ruano Y, Mollejo M, Ribalta T et al. Identification of novel candidate target genes in amplicons of glioblastoma multiforme tumors detected by expression and CGH microarray profiling. Mol. Cancer5, 39 (2006).
   PubMed Web of Science ®Google Scholar
• Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol.6(3), 217–223 (1996).
   PubMed Web of Science ®Google Scholar
• Tohma Y, Gratas C, Biernat W et al.PTEN (MMAC1 ) mutations are frequent in primary glioblastomas (de novo ) but not in secondary glioblastomas. J. Neuropathol. Exp. Neurol.57(7), 684–689 (1998).
   PubMed Web of Science ®Google Scholar
• Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R. Epidermal growth factor receptor-mediated signal transduction in the development and therapy of gliomas. Clin. Cancer Res.12(24), 7261–7270 (2006).
   PubMed Web of Science ®Google Scholar
• Wong RW, Guillaud L. The role of epidermal growth factor and its receptors in mammalian CNS. Cytokine Growth Factor Rev.15(2–3), 147–156 (2004).
   PubMed Web of Science ®Google Scholar
• Moscatello DK, Holgado-Madruga M, Emlet DR, Montgomery RB, Wong AJ. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J. Biol. Chem.273(1), 200–206 (1998).
   PubMed Web of Science ®Google Scholar
• Lorimer IA, Lavictoire SJ. Activation of extracellular-regulated kinases by normal and mutant EGF receptors. Biochim. Biophys. Acta1538(1), 1–9 (2001).
   PubMed Web of Science ®Google Scholar
• Li B, Yuan M, Kim IA, Chang CM, Bernhard EJ, Shu HK. Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin. Oncogene23(26), 4594–4602 (2004).
   PubMed Web of Science ®Google Scholar
• Narita Y, Nagane M, Mishima K, Huang HJ, Furnari FB, Cavenee WK. Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res.62(22), 6764–6769 (2002).
   PubMed Web of Science ®Google Scholar
• Nagane M, Coufal F, Lin H, Bogler O, Cavenee WK, Huang HJ. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res.56(21), 5079–5086 (1996).
   PubMed Web of Science ®Google Scholar
• Sugawa N, Yamamoto K, Ueda S et al. Function of aberrant EGFR in malignant gliomas. Brain Tumor Pathol.15(1), 53–57 (1998).
   PubMedGoogle Scholar
• Lal A, Glazer CA, Martinson HM et al. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res.62(12), 3335–3339 (2002).
   PubMed Web of Science ®Google Scholar
• Steck PA, Pershouse MA, Jasser SA et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet.15(4), 356–362 (1997).
   PubMed Web of Science ®Google Scholar
• Li J, Yen C, Liaw D et al.PTEN , a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science275(5308), 1943–1947 (1997).
   PubMed Web of Science ®Google Scholar
• Dahia PL. PTEN, a unique tumor suppressor gene. Endocr. Relat. Cancer7(2), 115–129 (2000).
   PubMed Web of Science ®Google Scholar
• Knobbe CB, Merlo A, Reifenberger G. Pten signaling in gliomas. Neuro-oncology4(3), 196–211 (2002).
   PubMed Web of Science ®Google Scholar
• Myers MP, Stolarov JP, Eng C et al. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc. Natl Acad. Sci. USA94(17), 9052–9057 (1997).
   PubMed Web of Science ®Google Scholar
• Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem.273(22), 13375–13378 (1998).
   PubMed Web of Science ®Google Scholar
• Cantley LC. The phosphoinositide 3-kinase pathway. Science296(5573), 1655–1657 (2002).
   PubMed Web of Science ®Google Scholar
• Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science280(5369), 1614–1617 (1998).
   PubMed Web of Science ®Google Scholar
• Dey N, Crosswell HE, De P et al. The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res.68(6), 1862–1871 (2008).
   PubMed Web of Science ®Google Scholar
• Raftopoulou M, Etienne-Manneville S, Self A, Nicholls S, Hall A. Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. Science303(5661), 1179–1181 (2004).
   PubMed Web of Science ®Google Scholar
• Li Y, Guessous F, Kwon S et al. PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations. Cancer Res.68(6), 1723–1731 (2008).
   PubMed Web of Science ®Google Scholar
• Watanabe K, Sato K, Biernat W et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin. Cancer Res.3(4), 523–530 (1997).
   PubMed Web of Science ®Google Scholar
• Reifenberger G, Reifenberger J, Ichimura K, Meltzer PS, Collins VP. Amplification of multiple genes from chromosomal region 12q13–14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res.54(16), 4299–4303 (1994).
   PubMed Web of Science ®Google Scholar
• Nakamura M, Watanabe T, Klangby U et al. p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol.11(2), 159–168 (2001).
   PubMed Web of Science ®Google Scholar
• Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer6(12), 909–923 (2006).
   PubMed Web of Science ®Google Scholar
• Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumor initiating cells. Nature432(7015), 396–401 (2004).
   PubMed Web of Science ®Google Scholar
• Galderisi U, Cipollaro M, Giordano A. Stem cells and brain cancer. Cell Death Differ.13(1), 5–11 (2006).
   PubMed Web of Science ®Google Scholar
• Meletis K, Wirta V, Hede SM et al. p53 suppresses the self-renewal of adult neural stem cells. Development133(2), 363–369 (2006).
   PubMed Web of Science ®Google Scholar
• Lin T, Chao C, Saito S et al. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat. Cell Biol.7(2), 165–171 (2005).
   PubMed Web of Science ®Google Scholar
• Puduvalli VK, Kyritsis AP, Hess KR et al. Patterns of expression of Rb and p16 in astrocytic gliomas, and correlation with survival. Int. J. Oncol.17(5), 963–969 (2000).
   PubMed Web of Science ®Google Scholar
• Flemington EK, Speck SH, Kaelin WG Jr. E2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. Proc. Natl Acad. Sci. USA,90(15), 6914–6918 (1993).
   PubMed Web of Science ®Google Scholar
• Helin K, Harlow E, Fattaey A. Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein. Mol. Cell Biol.13(10), 6501–6508 (1993).
   PubMed Web of Science ®Google Scholar
• Cobrinik D. Pocket proteins and cell cycle control. Oncogene24(17), 2796–2809 (2005).
   PubMed Web of Science ®Google Scholar
• Rich JN, Reardon DA, Peery T et al. Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol.22(1), 133–142 (2004).
   PubMed Web of Science ®Google Scholar
• Prados MD, Lamborn KR, Chang S et al. Phase I study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro-oncology8(1), 67–78 (2006).
   PubMed Web of Science ®Google Scholar
• Eoli M, Menghi F, Bruzzone MG et al. Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin. Cancer Res.13(9), 2606–2613 (2007).
   PubMed Web of Science ®Google Scholar
• Stupp R, Dietrich PY, Ostermann Kraljevic S et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol.20(5), 1375–1382 (2002).
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Godard S et al. Clinical trial substantiated the predictive value of 0–6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin. Cancer Res.10(6), 1871–1874 (2004).
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolamide in glioblastoma. N. Engl. J. Med.352(10), 997–1003 (2005).
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van der Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352(10), 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Landes ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature409(6822), 860–921 (2001).
   PubMed Web of Science ®Google Scholar
• Humphery-Smith I. A human proteome project with a beginning and an end. Proteomics4(9), 2519–2521 (2004).
   PubMed Web of Science ®Google Scholar
• Schwartz SA, Weil RJ, Thompson RC et al. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res.65(17), 7674–7681 (2005).
   PubMed Web of Science ®Google Scholar
• Bouamrani A, Ternier J, Ratel D et al. Direct-tisse SELDI-TOF mass spectrometry analysis: a new application for clinical proteomics. Clin. Chem.52(11), 2103–2106 (2006).
   PubMed Web of Science ®Google Scholar
• Furuta M, Weil RJ, Vortmeyer AO et al. Protein patterns and proteins that identify subtypes of glioblastoma multiforme. Oncogene23(40), 6806–6814 (2004).
   PubMed Web of Science ®Google Scholar
• Hobbs SK, Shi G, Homer R, Harsh G, Atlas SW, Bednarski MI. Magnetic resonance image-guided proteomics of human glioblastoma multiforme. J. Magn. Reson. Imaging18(5), 530–536 (2003).
   PubMed Web of Science ®Google Scholar
• Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific antigen and its complex with α1-antichymotrypsin before diagnosis of prostate cancer. Lancet344(8937), 1594–1598 (1994).
   PubMed Web of Science ®Google Scholar
• Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer5(11), 845–856 (2005).
   PubMed Web of Science ®Google Scholar
• Petrik V, Saadoun S, Loosemore A et al. Serum α2-HS glycoprotein predicts survival in patients with glioblastoma. Clin. Chem.54(4), 713–722 (2008).
   PubMed Web of Science ®Google Scholar
• Laws ER, Parney IF, Huang W et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the glioma outcomes project. J. Neurosurg.99(3), 467–473 (2003).
   PubMed Web of Science ®Google Scholar
• Devaux BC, O’Fallon JR, Kelly PJ.Resection, biopsy, and survival in malignant glial neoplasms: a retrospective study of clinical parameters, therapy and outcome. J. Neurosurg.78(5), 767–775 (1993).
   PubMed Web of Science ®Google Scholar
• de la Iglesia N, Konopka G, Puram SV et al. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev.22(4), 449–462 (2008).
   PubMed Web of Science ®Google Scholar
• Hanash SM, Bobek MP, Rickman DS et al. Integrating cancer genomics and proteomics in the post-genome era. Proteomics2(1), 69–75 (2002).
   PubMed Web of Science ®Google Scholar
• Nicoloso MS, Calin GA. MicroRNA involvement in brain tumors: from bench to bedside. Brain Pathol.18(1), 122–129 (2008).
   PubMed Web of Science ®Google Scholar
• Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res.65(14), 6029–6033 (2005).
   PubMed Web of Science ®Google Scholar
• Medina R, Zaidi SK, Liu CG et al. MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res.68(8), 2773–2780 (2008).
   PubMed Web of Science ®Google Scholar
• Kefas B, Godlewski J, Comeau L et al. MicroRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res.68(10), 3566–3572 (2008).
   PubMed Web of Science ®Google Scholar
• Ciafré SA, Galardi S, Mangiola A et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem. Biophys. Res. Commun.334(4), 1351–1358 (2005).
   PubMed Web of Science ®Google Scholar
• Hsu CW, Juan HF, Huang HC. Characterization of microRNA-regulated protein-protein interaction network. Proteomics8(10), 1975–1979 (2008).
   PubMed Web of Science ®Google Scholar
• Liu G, Wong-Staal F, Li QX. Development of new RNAi therapeutics. Histol. Histopathol.22(2), 211–217 (2007).
   PubMed Web of Science ®Google Scholar
• Corsten MF, Miranda R, Kasmieh R, Krichevsky AM, Weissleder R, Shah K. MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res.67(19), 8994–9000 (2007).
   PubMed Web of Science ®Google Scholar
• Krutzfeldt J, Rajewsky N, Braich R et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature438(7068), 685–689 (2005).
   PubMed Web of Science ®Google Scholar
• Weiler J, Hunziker J, Hall J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene Ther.13(6), 496–502 (2006).
   PubMed Web of Science ®Google Scholar
• German JB, Hammock BD, Watkins SM. Metabolomics: building on a century of biochemistry to guide human health. Metabolomics1(1), 3–9 (2005).
   PubMed Web of Science ®Google Scholar
• Lindon JC, Holmes E, Nicholson JK. Metabonomics and its role in drug development and disease diagnosis. Expert Rev. Mol. Diag.4(2), 89–99 (2004).
   Web of Science ®Google Scholar
• Griffin JL, Kauppinen RA. A metabolomics perspective of human brain tumours. FEBS J.274(5), 1132–1139 (2007).
   PubMed Web of Science ®Google Scholar
• Lindon JC, Nicholson JK, Holmes E et al. Contemporary issues in toxicology the role of metabonomics in toxicology and its evaluation by the COMET project. Toxicol. Appl. Pharmacol.187(3), 137–146 (2003).
   PubMed Web of Science ®Google Scholar
• Kitano H. Systems biology: a brief overview. Science295(5560), 1662–1664 (2002).
   PubMed Web of Science ®Google Scholar
• Ideker T, Galitski T, Hood L. A new approach to decoding life: systems biology. Annu. Rev. Genomics Hum. Genet.2, 343–372 (2001).
   PubMed Web of Science ®Google Scholar
• van der Greef J, Martin S, Juhasz P et al. The art and practice of systems biology in medicine: mapping patterns of relationships. J. Proteome Res.6(4), 1540–1559 (2007).
   PubMed Web of Science ®Google Scholar
• Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Statist. Soc. B57(1), 289–300 (1995).
   Web of Science ®Google Scholar
• Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl Acad. Sci. USA98(9), 5116–5121 (2001).
   PubMed Web of Science ®Google Scholar
• Steuer R, Kurths J, Fiehn O, Weckwerth W. Interpreting correlations in metabolomic networks. Biochem. Soc. Trans.31(Pt 6), 1476–1478 (2003).
   PubMed Web of Science ®Google Scholar
• Steuer R, Kurths J, Fiehn O, Weckwerth W. Observing and interpreting correlations in metabolomic networks. Bioinformatics19(8), 1019–1026 (2003).
   PubMed Web of Science ®Google Scholar